Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenip Plc Regulatory News (GNIP)

Share Price Information for Genip Plc (GNIP)

Share Price is delayed by 15 minutes
Get Live Data
4.65    0.00 (0.00%)
Bid:
4.50
Ask:
4.80
Spread: 0.30 (6.667%)
Market Cap: £1.19m
GNIP Live PriceLast checked at - London Stock Exchange

Intraday Genip Plc Share Chart

Strategic Partnership

15 Sep 2025 07:00

RNS Number : 2342Z
GenIP PLC
15 September 2025
 

 

15 September 2025 

 

GenIP Plc

("GenIP" or the "Company")

 

Strategic Partnership

 

GenIP Plc, a technology consultancy providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, has been appointed official technology transfer services provider to the Chile-based GreenTech Innovation Platform as part of its strategic partnership with the Universidad Autónoma de Chile.

 

The GreenTech Innovation Platform is used by over 400 members who have the potential to be GenIP clients, including universities, corporates, entrepreneurs, and public sector organisations, fostering collaboration to accelerate sustainable innovation in sectors such as commerce, services, and tourism.

 

The platform features tools for continuing education, events, talent recruitment, funding opportunities, and technological services, with a flagship program called InnovaSprint that provides $2,000,000 in funding for winning innovation projects.

 

As the platform's official technology transfer services provider, GenIP gains direct access to a high-quality pipeline of potential clients, offering its AI-powered evaluation, commercialisation, and talent-matching solutions to a growing regional innovation ecosystem.

 

Find out more about Universidad Autónoma de Chile here: https://www.uautonoma.cl/

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"Being named the official technology transfer partner to such a well-connected innovation platform positions GenIP at the heart of a vibrant and expanding market in Latin America. This partnership provides direct access to over 400 potential clients and collaborators, supporting our strategy to drive growth through high-value global networks."

 

Daniela Fuentes Contreras, TTO Director at Universidad Autónoma de Chile, commented:

 

"Partnering with GenIP brings world-class expertise in technology evaluation, commercialisation, and talent connection to our GreenTech Innovation Platform. This collaboration will strengthen our capacity to help innovations from Chile and Latin America reach global markets, creating tangible benefits for our community and the region's economy."

 

 

For further information regarding GenIP, please visit www.genip.ai, or contact:

 

GenIP Plc

Melissa Cruz, CEO 

Via Redchurch Communications

Novum Securities Limited (Broker) 

Jon Belliss

Tel: +44 (0)20 7399 9425

JBelliss@novumsecurities.com

 

 

Redchurch Communications (Financial PR)

John Casey

 

 

genip@weareredchurch.com

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

Notes to Editors

 

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary services:

 

1. Invention Evaluator: Provides bespoke research reports that assess the market potential of new technological innovations and discoveries using AI-driven proprietary software; and

 

2. Vortechs: which is an executive recruitment service that uses advanced machine learning algorithms and natural language processing technologies to assist in matching technology organisations with experienced executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help organisations to evaluate and commercialise their technological innovations. 

 

Company Strategy

 

GenIP's goal is to be a leading Generative AI analytic services company. To achieve this, the Company has established three strategic pillars:

 

· Organically grow Invention Evaluator and Vortechs' revenue through institutional and corporate connections as well as increase client pipeline through marketing, advertising and social media spend.

· Expand the Generative AI service offerings within Invention Evaluator and Vortechs' to reach new customers and improve margins.

· Bolt-on acquisitions of additional Generative AI services that are helpful to our clients and have demonstrated initial market traction. 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRALIMATMTTBBBA
Date   Source Headline
24th Jun 20265:18 pmRNSResult of AGM
24th Jun 20267:00 amRNS-RGenIP Innovation Roundtable
29th May 20265:52 pmRNSTotal Voting Rights
27th May 20267:00 amRNSAudited Final Results FY25 and Notice of AGM
21st May 20267:00 amRNSNew Orders
5th May 202611:35 amRNSTR-1: Notification of major holdings
1st May 20267:00 amRNSShare Placing to raise £350,000 and TVR
28th Apr 20267:00 amRNSStrategic Resale Alliance with Cardinal IP
31st Mar 20267:00 amRNS-RCommercial Update
10th Feb 20267:00 amRNS-RSales and Product Update
15th Jan 20267:00 amRNSCorporate Update
4th Dec 20257:00 amRNSOperational Update, Placing and TVR
21st Nov 20257:00 amRNS-RNew Report Orders From Repeat Clients
13th Nov 20257:00 amRNSTrading Statement
15th Oct 20257:00 amRNS-RTechnology Park Alliance
10th Oct 20257:00 amRNSNew Product Launch – Invention Validator
6th Oct 20257:00 amRNSReplacement RNS: Half-year Report
30th Sep 20257:02 amRNSCommercial Strategy Update & New Products
30th Sep 20257:00 amRNSHalf-year Report
24th Sep 20257:00 amRNS-RStrategic Partnership
15th Sep 20257:00 amRNS-RStrategic Partnership
25th Jul 20257:00 amRNSTrading Statement
1st Jul 20257:00 amRNS-RGenIP Secures First UK Academic Clients
26th Jun 20255:07 pmRNSResult of AGM
10th Jun 20257:00 amRNSContract Win
4th Jun 20257:00 amRNSAudited Results for Period Ended 31 December 2024
2nd Jun 20256:27 pmRNSNotice of AGM
29th May 20257:00 amRNS-RBusiness Update
7th May 20257:00 amRNS-RGenIP to attend 2025 AUTM Canadian Region Meeting
1st May 20257:00 amRNS-RNew Product Launch
31st Mar 20255:34 pmRNSUnaudited Results to 31 December 2024
26th Mar 20257:00 amRNS-RContract Win
20th Mar 20257:00 amRNS$0.35m Contract Win
13th Mar 20257:00 amRNSCorporate Update & 2025 Outlook
11th Feb 20257:00 amRNS-RGenIP to Sponsor the AUTM 2025 Annual Meeting
3rd Dec 20245:29 pmRNSTR-1: Notification of major holdings
20th Nov 20247:00 amRNSCorporate Update
8th Oct 20247:00 amRNSCorporate Update
2nd Oct 20247:00 amRNSAdmission to Trading on AIM-First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.